BaroFeron (IFN-β-1b) / Pressure BioSciences, Inc., Nuron Biotech  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BaroFeron (IFN-β-1b) / Nuron Biotech, Pressure BioSciences, Inc.
NCT01464905 / 2011-002683-24: Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Unknown status
3
500
Europe, RoW
NU100, Placebo, rhIFN beta-1b
Nuron Biotech Inc.
Relapsing Remitting Multiple Sclerosis
12/13
12/14

Download Options